Acute kidney injury (AKI) complicates pharmaceutical treatment because decreased renal clearance, drug distribution and uncertain renal recovery can all enhance toxicity or jeopardize therapeutic effectiveness. Traditional dose adjustments based on isolated serum creatinine measurements may be insufficient because creatinine kinetics lag behind changes in renal function. This review suggests a dynamic, pharmacist-led approach for customized drug treatment as AKI progresses and recovers. The framework includes medication reconciliation, serial renal function testing, urine output, fluid balance, hemodynamic state and kidney replacement therapy requirements. Pharmacists can detect nephrotoxic exposures, determine whether treatment is necessary, prioritize medication-related risks, optimize dose regimens and assist with therapeutic drug monitoring. Antimicrobial stewardship and review of high-risk medications are critical to avoiding overexposure and inadvertent undertreatment. Structured communication, documentation and specific review triggers can improve collaboration between pharmacists, prescribers and nephrologists. Electronic clinical decision-support systems may enable prompt intervention, but their usefulness is dependent on data quality, workflow integration and clinical interpretation. Medication review is also required during care transitions to ensure that temporary dose reductions and medication holds are evaluated and important therapies are properly resumed. Individual medication-safety treatments have shown promise, but the efficacy of an integrated, trajectory-guided pharmacist-led framework has yet to be proven. To determine the feasibility and clinical utility of the framework, prospective multicentre studies should assess medication appropriateness, preventable adverse drug events, treatment effectiveness, resource utilization and patient-centered outcomes.
Loading....